GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of am I the only one who found orforglipron harder than the injections — 60 comments in the full submission. View in context.
704
c/orforglipron·submitted 11 months ago by u/piotr_bruun

am I the only one who found orforglipron harder than the injections

Trial Databranch of 6 comments

am I the only one who found orforglipron harder than the injections. If this has been answered properly somewhere, link me and I will delete. Daily rather than weekly sounds trivial until you think about what a missed dose means in each case. Milligram comparisons across molecule classes are meaningless. Potency is a…

Read the full submission and all 60 comments →

This branch

6 comments, started 11 months ago
u/yara_boateng56 points·11 months ago

Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.

replysharereportpermalink
u/piotr_bruunOP66 points·11 months ago

Went looking for independent testing on this and found essentially nothing, which was clarifying.

replysharereportpermalink
u/cato_batista37 points·11 months ago

Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.

replysharereportpermalink
u/deleted_my_history17 points·11 months ago

Spent an evening reading about small-molecule agonism at a peptide receptor.

Adding the standing caveat — unapproved, and research material is not for human use.

replysharereportpermalink
u/marit_coelho26 points·11 months ago

Spent an evening reading about small-molecule agonism at a peptide receptor.

cato_batista is right that milligram comparisons across classes tell you nothing.

replysharereportpermalink
u/trialwatch_theoMOD31 points·11 months ago

Corrected a cross-class dose comparison in the title. The body is untouched.

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →